{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:03:51Z","timestamp":1790370231986,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/onc.2016.362","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T10:09:45Z","timestamp":1475489385000},"page":"2066-2073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["MYC selects against reduced BCL2A1\/A1 protein expression during B cell lymphomagenesis"],"prefix":"10.1038","volume":"36","author":[{"given":"M","family":"Sochalska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J G","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Prchal-Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Sexl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Villunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"BFonc2016362_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.seminhematol.2014.05.008","volume":"51","author":"MA Anderson","year":"2014","unstructured":"Anderson MA, Huang D, Roberts A . Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51: 219\u2013227.","journal-title":"Semin Hematol"},{"key":"BFonc2016362_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"AR Delbridge","year":"2015","unstructured":"Delbridge AR, Strasser A . The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 2015; 22: 1071\u20131080.","journal-title":"Cell Death Differ"},{"key":"BFonc2016362_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171\u2013185.","journal-title":"Cancer Cell"},{"key":"BFonc2016362_CR4","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1182\/blood-2011-07-367672","volume":"118","author":"PN Kelly","year":"2011","unstructured":"Kelly PN, Grabow S, Delbridge AR, Strasser A, Adams JM . Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 2011; 118: 6380\u20136386.","journal-title":"Blood"},{"key":"BFonc2016362_CR5","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2006-10-051847","volume":"109","author":"PN Kelly","year":"2007","unstructured":"Kelly PN, Puthalakath H, Adams JM, Strasser A . Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood 2007; 109: 4907\u20134913.","journal-title":"Blood"},{"key":"BFonc2016362_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.yexcr.2012.01.021","volume":"318","author":"E Ottina","year":"2012","unstructured":"Ottina E, Tischner D, Herold MJ, Villunger A . A1\/Bfl-1 in leukocyte development and cell death. Exp Cell Res 2012; 318: 1291\u20131303.","journal-title":"Exp Cell Res"},{"key":"BFonc2016362_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/cdd.2011.158","volume":"19","author":"M Vogler","year":"2011","unstructured":"Vogler M . BCL2A1: the underdog in the BCL2 family. Cell Death Differ 2011; 19: 67\u201374.","journal-title":"Cell Death Differ"},{"key":"BFonc2016362_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ijc.20614","volume":"113","author":"AA Morales","year":"2005","unstructured":"Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM . High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730\u2013737.","journal-title":"Int J Cancer"},{"key":"BFonc2016362_CR9","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403\u20134413.","journal-title":"Blood"},{"key":"BFonc2016362_CR10","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2011","unstructured":"Yecies D, Carlson NE, Deng J, Letai A . Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2011; 115: 3304\u20133313.","journal-title":"Blood"},{"key":"BFonc2016362_CR11","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1073\/pnas.1205575110","volume":"110","author":"R Haq","year":"2013","unstructured":"Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 2013; 110: 4321\u20134326.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016362_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/intimm\/10.5.631","volume":"10","author":"S Hatakeyama","year":"1998","unstructured":"Hatakeyama S, Hamasaki A, Negishi I, Loh DY, Sendo F, Nakayama K . Multiple gene duplication and expression of mouse bcl-2-related genes, A1. Int Immunol 1998; 10: 631\u2013637.","journal-title":"Int Immunol"},{"key":"BFonc2016362_CR13","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1038\/cddis.2016.23","volume":"7","author":"J Vier","year":"2016","unstructured":"Vier J, Groth M, Sochalska M, Kirschnek S . The anti-apoptotic Bcl-2 family protein A1\/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK\/STAT signaling. Cell Death Dis 2016; 7: e2103.","journal-title":"Cell Death Dis"},{"key":"BFonc2016362_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/cdd.2015.130","volume":"23","author":"M Sochalska","year":"2016","unstructured":"Sochalska M, Ottina E, Tuzlak S, Herzog S, Herold M, Villunger A . Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival. Cell Death Differ 2016; 23: 628\u2013639.","journal-title":"Cell Death Differ"},{"key":"BFonc2016362_CR15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4049\/jimmunol.1400637","volume":"194","author":"E Ottina","year":"2015","unstructured":"Ottina E, Lyberg K, Sochalska M, Villunger A, Nilsson G . Knockdown of the anti-apoptotic Bcl-2-family member A1\/Bfl-1 protects mice from anaphylaxis. J Immunol 2015; 194: 1316\u20131322.","journal-title":"J Immunol"},{"key":"BFonc2016362_CR16","doi-asserted-by":"publisher","first-page":"6032","DOI":"10.1182\/blood-2011-12-399089","volume":"119","author":"E Ottina","year":"2012","unstructured":"Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A et al. Targeting antiapoptotic A1\/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 2012; 119: 6032\u20136042.","journal-title":"Blood"},{"key":"BFonc2016362_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2011","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA et al. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol Med 2011; 2: 98\u2013110.","journal-title":"EMBO Mol Med"},{"key":"BFonc2016362_CR18","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1073\/pnas.0606176103","volume":"103","author":"J Kuroda","year":"2006","unstructured":"Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907\u201314912.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016362_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677\u2013681.","journal-title":"Nature"},{"key":"BFonc2016362_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533\u2013538.","journal-title":"Nature"},{"key":"BFonc2016362_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26: 120\u2013125.","journal-title":"Genes Dev"},{"key":"BFonc2016362_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1101\/gad.232009.113","volume":"28","author":"GL Kelly","year":"2014","unstructured":"Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58\u201370.","journal-title":"Genes Dev"},{"key":"BFonc2016362_CR23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","volume":"122","author":"W Warsch","year":"2013","unstructured":"Warsch W, Walz C, Sexl V . JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 2013; 122: 2167\u20132175.","journal-title":"Blood"},{"key":"BFonc2016362_CR24","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/febs.13188","volume":"282","author":"M Sochalska","year":"2015","unstructured":"Sochalska M, Tuzlak S, Egle A, Villunger A . Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J 2015; 282: 834\u2013849.","journal-title":"FEBS J"},{"key":"BFonc2016362_CR25","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1128\/MCB.21.15.5063-5070.2001","volume":"21","author":"CM Eischen","year":"2001","unstructured":"Eischen CM, Woo D, Roussel MF, Cleveland JL . Apoptosis triggered by myc-induced suppression of Bcl-XL or Bcl-2 Is bypassed during lymphomagenesis. Mol Cell Biol 2001; 21: 5063\u20135070.","journal-title":"Mol Cell Biol"},{"key":"BFonc2016362_CR26","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2009-08-236760","volume":"115","author":"G Fan","year":"2011","unstructured":"Fan G, Simmons MJ, Ge S, Dutta-Simmons J, Kucharczak J, Ron Y et al. Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 2011; 115: 3559\u20133569.","journal-title":"Blood"},{"key":"BFonc2016362_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/onc.2008.466","volume":"28","author":"LJ Beverly","year":"2009","unstructured":"Beverly LJ, Varmus HE . MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009; 28: 1274\u20131279.","journal-title":"Oncogene"},{"key":"BFonc2016362_CR28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.celrep.2014.07.057","volume":"8","author":"N Muthalagu","year":"2014","unstructured":"Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B et al. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Reports 2014; 8: 1347\u20131353.","journal-title":"Cell Reports"},{"key":"BFonc2016362_CR29","doi-asserted-by":"publisher","first-page":"17834","DOI":"10.1073\/pnas.0604129103","volume":"103","author":"KI Zeller","year":"2006","unstructured":"Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 2006; 103: 17834\u201317839.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2016362_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/cdd.2015.97","volume":"23","author":"MJ Carter","year":"2016","unstructured":"Carter MJ, Cox KL, Blakemore SJ, Bogdanov YD, Happo L, Scott CL et al. BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma. Cell Death Differ 2016; 23: 303\u2013312.","journal-title":"Cell Death Differ"},{"key":"BFonc2016362_CR31","doi-asserted-by":"publisher","first-page":"8133","DOI":"10.1128\/JVI.00278-06","volume":"80","author":"PM Pegman","year":"2006","unstructured":"Pegman PM, Smith SM, D'Souza BN, Loughran ST, Maier S, Kempkes B et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1\/RBPJ kappa-dependent pathway. J Virol 2006; 80: 8133\u20138144.","journal-title":"J Virol"},{"key":"BFonc2016362_CR32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.V94.6.1855","volume":"94","author":"S Ogilvy","year":"1999","unstructured":"Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM . Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood 1999; 94: 1855\u20131863.","journal-title":"Blood"},{"key":"BFonc2016362_CR33","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.1038\/cddis.2014.519","volume":"5","author":"MJ Lang","year":"2014","unstructured":"Lang MJ, Brennan MS, O'Reilly LA, Ottina E, Czabotar PE, Whitlock E et al. Characterisation of a novel A1-specific monoclonal antibody. Cell Death Dis 2014; 5: e1553.","journal-title":"Cell Death Dis"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2016362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016362","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2016362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:00:19Z","timestamp":1684472419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFonc2016362"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.362","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]},"assertion":[{"value":"13 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}